MSLE vs MTNB

Satellos Bioscience Inc. vs Matinas Biopharma Holdings, Inc — Valuation Comparison 2026

MSLE

Biotechnology
Satellos Bioscience Inc.
Quality
3.7
out of 10
Value Trap
Price
$7.03
Last close
Models
7/13
Active
VS

MTNB

Biotechnology
Matinas Biopharma Holdings, Inc
Quality
4.0
out of 10
Value Trap
31
LOW
Price
$0.79
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType MSLE Fair ValueMSLE Upside MTNB Fair ValueMTNB Upside
Bayesian DCF Intrinsic $2.96 -57.9% $0.47 -40.9%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $2.47 -64.9% $3.08 +287.3%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for MSLE vs MTNB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MSLE vs MTNB — Which Stock Is More Undervalued?

MTNB scores higher with a 4.0/10 quality rating vs MSLE's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Satellos Bioscience Inc. (MSLE) and Matinas Biopharma Holdings, Inc (MTNB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MSLE currently trades at $7.03 with a QOC of 3.7/10, while MTNB trades at $0.79 with a QOC of 4.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).